Cancer Discovery · 2019 · 105 citations · 32 references
MedicineCancer BiologyOncologyCancer GeneticsDna RepairMolecular OncologyCancer Cell SignalingDna Damage SignalingOncogenic Signaling PathwaysSignal Transduction In CancerSynthetic LethalityTargeted Cancer TherapyChemical Synthetic LethalityDna Damage Repair PathwaysDna Repair Pathway DefectsDna Repair PathwaysMek InhibitionMek InhibitorsNonhomologous End JoiningNonhomologous End Joining Defects
Abstract Although the majority of BRAF-mutant melanomas respond to BRAF/MEK inhibitors, these agents are not typically curative. Moreover, they are largely ineffective in NRAS- and NF1-mutant tumors. Here we report that genetic and chemical suppression of HDAC3 potently cooperates with MAPK pathway inhibitors in all three RAS pathway–driven tumors. Specifically, we show that entinostat dramatically enhances tumor regression when combined with BRAF/MEK inhibitors, in both models that are sensitive or relatively resistant to these agents. Interestingly, MGMT expression predicts responsiveness and marks tumors with latent defects in DNA repair. BRAF/MEK inhibitors enhance these defects by suppressing homologous recombination genes, inducing a BRCA-like state; however, addition of entinostat triggers the concomitant suppression of nonhomologous end-joining genes, resulting in a chemical synthetic lethality caused by excessive DNA damage. Together, these studies identify melanomas with latent DNA repair defects, describe a promising drug combination that capitalizes on these defects, and reveal a tractable therapeutic biomarker. Significance: BRAF/MEK inhibitors are not typically curative in BRAF-mutant melanomas and are ineffective in NRAS- and NF1-mutant tumors. We show that HDAC inhibitors dramatically enhance the efficacy of BRAF/MEK inhibitors in sensitive and insensitive RAS pathway–driven melanomas by coordinately suppressing two DNA repair pathways, and identify a clinical biomarker that predicts responsiveness. See related commentary by Lombard et al., p. 469. This article is highlighted in the In This Issue feature, p. 453
32
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Genomic Classification of Cutaneous Melanoma
Rehan Akbani, Kadir C. Akdemir, Bülent Arman Aksoy et al. · Cell · 2015 · 3.2K citations · Full text